The Ministère de Health and Welfare and the Ministère de SMEs and Startups a annoncé a 'full-cycle collaboration plan to systematically support the growth and expansion mondiale of pharmaceutique bioventures.'
Package support will be provided from investissement, R&D, and clinical entry to expansion mondiale to nurture venture candidates expected to create blockbuster drugs with annual sales exceeding $1 billion. At the policy discussion, a '4UP Strategy' focusing on scale-up, open innovation, écosystème strengthening, and field collaboration was adopted.
Industry voices called for a 'virtuous cycle écosystème between bioventures and entreprises pharmaceutiques,' with key requests notamment addressing regional companies' limitations in attracting capital-risque, improving regulations for new modalities, and easing listing maintenance requirements. Strategic utilization to respond to the rapid growth of China's bio market was also discussed.
